This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intuitive Surgical (ISRG) Beats on Q3 Earnings & Revenues
by Zacks Equity Research
Strong performance in the Instruments & Accessories and Systems segments drive Intuitive Surgical's (ISRG) top line in Q3.
Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.
Can Overall Growth Drive Align Technology (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q3.
Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.
Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed
by Zacks Equity Research
Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.
Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.
What's in Store for Cerner (CERN) This Earnings Season?
by Zacks Equity Research
Cerner's (CERN) third-quarter 2018 results are likely to be hurt by soft segmental results; guidance promising.
Will Instruments Drive Intuitive Surgical (ISRG) Q3 Earnings?
by Zacks Equity Research
Strong prospects in the Instruments and Accessories segment to drive Intuitive Surgical???s (ISRG) top line in the third quarter of 2018.
Varian Medical (VAR) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Solid prospects in the Oncology segment to boost Varian Medical's (VAR) top-line performance in the fourth quarter of fiscal 2018.
What's in Store for Express Scripts' (ESRX) Q3 Earnings?
by Zacks Equity Research
Express Scripts (ESRX) likely to see soft PBM revenues in the third quarter of 2018; guidance strong.
Cerner's Millennium Platform Integrated at McLaren Hospital
by Zacks Equity Research
Cerner's (CERN) Millennium HCIT platform sees a series of developments in 2018.
Can Baxter (BAX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Baxter & ASPEN Launch PN Tools to Boost Clinical Nutrition
by Zacks Equity Research
Baxter (BAX) and ASPEN's SmartPN lends the company a competitive edge in the MedTech space.
Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International
by Zacks Equity Research
Zacks.com highlights: Lululemon Athletica, Malibu Boats, Surmodics and Baxter International
Buy These 4 Efficient Stocks for Stellar Returns
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
Stryker's HyperBranch Buyout to Boost Neurotechnology Business
by Zacks Equity Research
Stryker's (SYK) craniomaxillofacial division's market prospects bright.
Baxter Collaborates With Mayo Clinic to Open Renal Care Center
by Zacks Equity Research
Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.
Baxter (BAX) Collaborates With USC CBC to Digitize Healthcare
by Zacks Equity Research
Baxter's (BAX) efforts to digitize healthcare solutions are likely to fortify its foothold in the highly competitive MedTech industry.
Stock Market News For Sep 27, 2018
by Zacks Equity Research
Wall Street ended lower on Wednesday following quarter point interest rate hike by the Fed.
Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod
by Zacks Equity Research
Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.
Accuray's CyberKnife Manages Prostate Cancer Effectively
by Zacks Equity Research
Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.
Here's Why You Should Buy Baxter International (BAX) Now
by Zacks Equity Research
Baxter's (BAX) raised guidance for 2018 and a series of approvals make it a promising investment pick.
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Innovation in stroke treatment with catheter-based technologies has launched a new rocket of med-tech
Stock Market News For Sept 7, 2018
by Zacks Equity Research
U.S. stock market closed mostly lower on Thursday as softness in tech sector, trade war concerns and fear of contagion from some emerging markets problems have rattled investor confidence
Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod
by Zacks Equity Research
The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.